Apps Purchases: 10+ Million Software Purchases
Founded in 2010, APPS RUN THE WORLD is a leading technology intelligence and market-research company devoted to the application space. Leveraging a rigorous data-centric research methodology, we ask the simple B2B sales intelligence question: Who’s buying enterprise applications from whom and why?
Our global team of 50 researchers has been studying the digital transformation initiatives being undertaken by 2 million + companies including technographic segmentation of 10 million ERP, EPM, CRM, HCM, Procurement, SCM, Treasury software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Apps Run The World Buyer Insight and Technographics Customer Database has over 100 data fields that detail company usage of emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database, and different on-prem and cloud apps by function, customer size (employees, revenues), industry, country, implementation status, year deal won, partner involvement, Line of Business Key Stakeholders and key decision-makers contact details, including the systems being used by Fortune 1000 and Global 2000 companies.
Apply Filters For 10+ Million Software Purchases
- Analytics and BI
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | VAR/SI | Insight | Insight Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck Germany | Life Sciences | 11000 | $3.6B | Germany | JMP Statistical Discovery | JMP Analytics | Analytics and BI | 2019 | n/a | In 2019, Merck Germany implemented JMP Analytics to support biomarker discovery and clinical biostatistics work at its Darmstadt site. The deployment targets biostatistics and clinical research teams and is framed under the Analytics and BI category to handle exploratory and regulatory-quality analyses of complex clinical datasets. The implementation emphasizes exploratory data analysis and interactive visualization capabilities within JMP Analytics, enabling statisticians to iterate on data visualizations, run statistical tests, and prepare reproducible analytical artifacts for regulatory review. Configuration prioritized workflows that support collaborative review between statisticians and subject-matter experts, and the environment was used for both discovery-oriented analysis and formal regulatory-quality reporting. Operational scope is concentrated in Germany, with biomarker research teams in Darmstadt as the primary users, and the platform is applied to multi-dimensional clinical datasets common in biomarker research. The deployment supports cross-functional collaboration between statistical teams and clinical researchers, improving data interpretation and accelerating hypothesis generation from complex trial and biomarker data. Governance and process adjustments focused on embedding statistical rigor into routine research workflows and fostering structured collaboration between statisticians and domain experts. Outcomes reported include improved statistical rigor and faster insight generation from clinical datasets, and the use of JMP Analytics for regulatory-quality analyses helped align exploratory findings with formal reporting requirements. | |
 |
Bayer UK | Life Sciences | 700 | $890M | United Kingdom | IBM | IBM Cognos Impromptu | Analytics and BI | 2000 | n/a | In 2000, Bayer UK implemented IBM Cognos Impromptu as part of a broader Cognos Series 7 deployment. The Analytics and BI implementation provided managed reporting and portal-based access for the UK and Ireland sales force to operational and financial data. The deployment included Impromptu Web Reports and centralized report cataloguing to support ad-hoc querying and scheduled reporting, simplifying report distribution through a portal interface. IBM Cognos Impromptu was configured to expose operational and financial subject areas to finance and sales users, reducing local report maintenance and enabling faster ad-hoc analysis. Data integration was improved as part of the deployment, reducing maintenance overhead and accelerating ad-hoc reporting workflows for finance and sales, and the implementation selected around 2000 was upgraded to Series 7 by 2002. Governance shifted toward managed reporting and portal access controls, establishing a single reporting layer for the UK and Ireland sales organization and finance teams. | |
 |
|
Life Sciences | 82878 | $47.7B | France | USU Solutions | USU SAM Analytics | Analytics and BI | 2022 | n/a |
|
|
|
|
|
Life Sciences | 120 | $20M | Ireland | Perfalytics | Freshpaint | Analytics and BI | 2024 | n/a |
|
|
|
|
|
Life Sciences | 1316 | $303M | Morocco | Google Charts | Analytics and BI | 2020 | n/a |
|
|
|
|
|
|
Life Sciences | 250 | $50M | Argentina | Google Charts | Analytics and BI | 2015 | n/a |
|
|
|
|
|
|
Life Sciences | 153 | $25M | Italy | LabWare | LabWare Mobile | Data Warehouse | 2022 | n/a |
|
|
|
|
|
Life Sciences | 250 | $35M | United States | MasterControl | MasterControl Insights | Analytics and BI | 2023 | n/a |
|
|
|
|
|
Life Sciences | 200 | $11M | India | Teradata | Teradata Aster Analytics | Analytics and BI | 2017 | n/a |
|
|
|
|
|
Life Sciences | 125000 | $42.9B | United States | SharpCloud | SharpCloud Platform | Analytics and BI | 2020 | n/a |
|
|